| abstract |
The present invention is bispecific, having at least one epitope binding site immunospecific for an epitope of PD-1 and at least one epitope binding site immunospecific for an epitope of CTLA-4. Molecules (eg, diabodies, bispecific antibodies, trivalent binding molecules, etc.) (ie, "PD-1 × CTLA-4 bispecific molecules") are of interest. The PD-1 × CTLA-4 bispecific molecule of the present invention can simultaneously bind to PD-1 and CTLA-4, particularly when the molecule is arranged on the human cell surface. The present invention is directed to pharmaceutical compositions containing the PD-1 × CTLA-4 bispecific molecules described above, as well as methods involving the use of the bispecific molecules described above in the treatment of cancer and other diseases or conditions. I assume. The invention also relates to methods of stimulating an immune response using the PD-1 × CTLA-4 bispecific molecule described above. [Selected figure] Fig. 18 |